HUMAN GENOME SCIENCES INC Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2012-08: Study NCT01670565; Company role Collaborator; Phase Phase 2; Status Completed.
- 2012-06-11: Study NCT01597622; Company role Collaborator; Phase Phase 3; Status Completed.
- 2011-12: Study NCT01434576; Company role Lead sponsor; Phase Phase 1; Status Withdrawn.
- 2011-05-23: Study NCT01345253; Company role Collaborator; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2012-08 | NCT01670565 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis | Collaborator Lead: Hospital for Special Surgery, New York | Phase 2 | Completed Results posted | Systemic Sclerosis | 20 | 2016-02 |
| 2012-06-11 | NCT01597622 BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 | Collaborator Lead: GlaxoSmithKline | Phase 3 | Completed Results posted | Systemic Lupus Erythematosus | 142 | 2018-09-13 |
| 2011-12 | NCT01434576 Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis | Lead sponsor | Phase 1 | Withdrawn | Ulcerative Colitis | 0 | |
| 2011-05-23 | NCT01345253 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia | Collaborator Lead: GlaxoSmithKline | Phase 3 | Completed Results posted | Systemic Lupus Erythematosus | 709 | 2018-09-21 |
| 2011-02 | NCT01583530 Study of Belimumab Administered Subcutaneously to Healthy Subjects | Lead sponsor | Phase 1 | Completed Results posted | Healthy | 118 | 2011-09 |
| 2010-03 | NCT01160666 Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome | Collaborator Lead: Assistance Publique - Hôpitaux de Paris | Phase 2 | Completed | Sjögren's Syndrome | 20 | 2012-06 |
| 2010-03 | NCT01088347 Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer | Collaborator Lead: University Medical Center Groningen | Phase 1, Phase 2 | Completed | Advanced Cervical Cancer | 9 | 2014-03 |
| 2010-02 | NCT01025193 Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant | Collaborator Lead: University of Pennsylvania | Phase 2 | Terminated Results posted | Desensitization | 8 | 2011-11 |
| 2009-11 | NCT01142011 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia | Collaborator Lead: Cancer Trials Australia | Phase 2 | Unknown | Symptomatic Waldenstroms Macroglobulinaemia | 15 | 2013-01 |
| 2009-10 | NCT01013818 A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies | Lead sponsor | Phase 1 | Terminated | Lymphoid Malignancies | 11 | 2011-10 |
| 2009-07 | NCT01914770 Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76 | Collaborator Lead: GlaxoSmithKline | Observational | Completed | Systemic Lupus Erythematosus | 1,016 | 2010-11 |
| 2009-07 | NCT00964665 Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects | Collaborator Lead: Novartis Pharmaceuticals | Phase 1, Phase 2 | Terminated | Chronic Hepatitis B | 141 | |
| 2008-10 | NCT00759200 Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients | Collaborator Lead: Novartis | Phase 2 | Completed | Chronic Hepatitis C | 525 | 2010-12 |
| 2008-10 | NCT00732940 Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) | Lead sponsor | Phase 2 | Terminated Results posted | Systemic Lupus Erythematosus | 56 | 2012-03 |
| 2008-05 | NCT00708006 A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed | Advanced Solid Tumors | 66 | 2012-01 |
| 2008-03 | NCT00639678 A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects | Lead sponsor | Phase 3 | Completed Results posted | Healthy | 322 | 2008-09 |
| 2008-01-31 | NCT02016963 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | Therapeutic Treatment of Inhalation Anthrax | 20 | 2008-05-31 |
| 2007-05 | NCT00424476 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | Lead sponsor | Phase 3 | Completed Results posted | Systemic Lupus Erythematosus | 865 | 2010-03 |
| 2007-02 | NCT00411385 Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3 | Lead sponsor | Phase 3 | Completed | Chronic Hepatitis C | 933 | 2008-10 |
| 2007-01 | NCT00583830 A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer | Lead sponsor | Phase 2 | Completed | Non Small Cell Lung Cancer | 111 | 2011-02 |
| 2006-12 | NCT00410384 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | Lead sponsor | Phase 3 | Completed Results posted | Systemic Lupus Erythematosus | 819 | 2010-03 |
| 2006-12 | NCT00402428 Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients | Lead sponsor | Phase 3 | Completed | Chronic Hepatitis C | 1,331 | 2009-02 |
| 2006-05 | NCT00315757 Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | Lead sponsor | Phase 2 | Completed | Multiple Myeloma | 105 | 2010-10 |
| 2005-11 | NCT00656006 A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 | Lead sponsor | Phase 2 | Completed | Chronic Hepatitis C | 43 | 2007-04 |
| 2005-05 | NCT00115908 A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1 | Lead sponsor | Phase 2 | Completed | Hepatitis C, Chronic | 458 | 2007-05 |
| 2005-04 | NCT00114699 Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy | Lead sponsor | Phase 1 | Completed | HIV Infections | 40 | 2006-04 |
| 2005-01 | NCT00583557 A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01 | Lead sponsor | Phase 2 | Terminated Results posted | Rheumatoid Arthritis | 155 | 2009-11 |
| 2004-10 | NCT00097435 A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C | Lead sponsor | Phase 2 | Completed | Hepatitis C | 115 | 2007-08 |
| 2004-06 | NCT00094848 Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | Lead sponsor | Phase 2 | Completed | Lymphoma, Non-Hodgkin | 2007-05 | |
| 2003-12 | NCT00071812 A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) | Lead sponsor | Phase 2 | Completed Results posted | Arthritis, Rheumatoid | 283 | 2005-12 |
| 2003-10 | NCT00071487 Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) | Lead sponsor | Phase 2 | Completed Results posted | Lupus Erythematosus, Systemic | 449 | 2006-06 |
| 2002-02 | NCT00657007 Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | Lead sponsor | Phase 1 | Completed | Systemic Lupus Erythematosus | 70 | 2003-03 |
| NCT00092924 Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) | Lead sponsor | Phase 2 | Completed | Carcinoma, Non-Small-Cell Lung | 2005-03 |